[
  {
    "ts": null,
    "headline": "Cytokinetics: Approval Catalyst In December - But Risk Reward Is Not Compelling",
    "summary": "Cytokinetics, Incorporated awaits a pivotal FDA decision on aficamten for hypertrophic cardiomyopathy. Learn more about CYTK stock here.",
    "url": "https://finnhub.io/api/news?id=c4bcc9205295587e3d9ed5e85fa36f49c0c4981202c1aed7182eb2529b8a5c33",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763738912,
      "headline": "Cytokinetics: Approval Catalyst In December - But Risk Reward Is Not Compelling",
      "id": 137573195,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2216601425/image_2216601425.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Cytokinetics, Incorporated awaits a pivotal FDA decision on aficamten for hypertrophic cardiomyopathy. Learn more about CYTK stock here.",
      "url": "https://finnhub.io/api/news?id=c4bcc9205295587e3d9ed5e85fa36f49c0c4981202c1aed7182eb2529b8a5c33"
    }
  },
  {
    "ts": null,
    "headline": "This Medical Technology Leader Sees Profit Growth Topping 44%",
    "summary": "The medical technology stock is in a consolidation pattern and testing a key level. The biotech had a beat-and-raise quarter.",
    "url": "https://finnhub.io/api/news?id=812f2c9eb0ee56f7ad60bb56c7bc3d83a7821c676acb7d8cc96e4c9ef6e745b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763730034,
      "headline": "This Medical Technology Leader Sees Profit Growth Topping 44%",
      "id": 137572025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The medical technology stock is in a consolidation pattern and testing a key level. The biotech had a beat-and-raise quarter.",
      "url": "https://finnhub.io/api/news?id=812f2c9eb0ee56f7ad60bb56c7bc3d83a7821c676acb7d8cc96e4c9ef6e745b7"
    }
  },
  {
    "ts": null,
    "headline": "PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms",
    "summary": "Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.",
    "url": "https://finnhub.io/api/news?id=057630b543edc31b29ebefc8c520e7b265def2a2f0c556ac5203d3261213b47f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763728860,
      "headline": "PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms",
      "id": 137572198,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.",
      "url": "https://finnhub.io/api/news?id=057630b543edc31b29ebefc8c520e7b265def2a2f0c556ac5203d3261213b47f"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: I See No Catalysts To Break Underperformance",
    "summary": "Bristol-Myers Squibb (BMY) faces a severe patent cliff, risking up to 60% of recent revenues as key blockbusters lose exclusivity.",
    "url": "https://finnhub.io/api/news?id=9f61281c7bb948310935b3869f8f405298ddd95c17a224475ac2336a3a6baa26",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763712050,
      "headline": "Bristol-Myers Squibb: I See No Catalysts To Break Underperformance",
      "id": 137568755,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160008492/image_2160008492.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb (BMY) faces a severe patent cliff, risking up to 60% of recent revenues as key blockbusters lose exclusivity.",
      "url": "https://finnhub.io/api/news?id=9f61281c7bb948310935b3869f8f405298ddd95c17a224475ac2336a3a6baa26"
    }
  }
]